

CITATION REPORT

List of articles citing

Biosimilars: A Value Proposition

DOI: 10.1007/s40259-019-00360-7
BioDrugs, 2019, 33, 353-356.

Source: <https://exaly.com/paper-pdf/73023361/citation-report.pdf>

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
15	Comment on: "Efficacy and Safety of Supportive Care Biosimilars Among Cancer Patients: A Systematic Review and Meta-Analysis". <i>BioDrugs</i> , 2019 , 33, 583-584	7.9	2
14	Biosimilar and interchangeable: Inseparable scientific concepts?. <i>British Journal of Clinical Pharmacology</i> , 2019 , 85, 2460-2463	3.8	9
13	Identifying Key Benefits in European Off-Patent Biologics and Biosimilar Markets: It is Not Only About Price!. <i>BioDrugs</i> , 2020 , 34, 159-170	7.9	33
12	Clinical and Regulatory Considerations for the Use of Bevacizumab Biosimilars in Metastatic Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , 2021 , 20, 42-51.e3	3.8	2
11	Technological Advancements in Monoclonal Antibodies. <i>Scientific World Journal, The</i> , 2021 , 2021, 6663708	0	2
10	Extrapolation: Experience gained from original biologics. <i>Drug Discovery Today</i> , 2021 , 26, 2003-2013	8.8	3
9	[Knowledge and perceptions of biosimilar medicines by health professionals in Tunisia]. <i>Annales Pharmaceutiques Francaises</i> , 2021 ,	1.3	0
8	Safety, Immunogenicity and Interchangeability of Biosimilar Monoclonal Antibodies and Fusion Proteins: A Regulatory Perspective. <i>Drugs</i> , 2021 , 81, 1881-1896	12.1	6
7	Is the Compulsory Licensing Mechanism Guaranteed by TRIPS the Best Remedy to Improve Access to Biological Therapies Worldwide?. <i>Eastern European Journal of Transnational Relations</i> , 2019 , 3, 39-52	0	0
6	Efficacy and immunogenicity of insulin biosimilar compared to their reference products: a systematic review and meta-analysis.. <i>BMC Endocrine Disorders</i> , 2022 , 22, 35	3.3	1
5	Overlapping biosimilar and originator follitropin alfa preparations: How much closer can they get?. <i>Drug Discovery Today</i> , 2022 ,	8.8	0
4	Effectiveness and Safety of Filgrastim (Neupogen) versus Filgrastim-aafi (Nivestim) in Primary Prophylaxis of Chemotherapy-Induced Febrile Neutropenia: An Observational Cohort Study.	0	0
3	Biosimilars: Science, Implications, and Potential Outlooks in the Middle East and Africa. Volume 16, 161-171	0	0
2	Expanding access to biotherapeutics in low-income and middle-income countries through public health non-exclusive voluntary intellectual property licensing: considerations, requirements, and opportunities. 2023 , 11, e145-e154	0	2
1	Factors influencing bioequivalence evaluation of insulin biosimilars based on a structural equation model. 14,	0	0